BDBM359614 N-[(1-Aminoisoquinolin-6-yl)methyl]-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)pyridine-3-carboxamide::US10221161, Example 1

SMILES: Cc1cnn(Cc2ccc(Cc3cncc(c3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1

InChI Key: InChIKey=XZGMSMZMNPUQHT-UHFFFAOYSA-N

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 359614   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Kallikrein 1 (Homo sapiens (Human))	BDBM359614 (N-[(1-Aminoisoquinolin-6-yl)methyl]-({4-[(4-methyl...) Show SMILES Cc1cnn(Cc2ccc(Cc3cncc(c3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 Show InChI InChI=1S/C28H26N6O/c1-19-13-33-34(17-19)18-21-4-2-20(3-5-21)10-23-12-25(16-30-14-23)28(35)32-15-22-6-7-26-24(11-22)8-9-31-27(26)29/h2-9,11-14,16-17H,10,15,18H2,1H3,(H2,29,31)(H,32,35)	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...				US Patent US10221161 (2019) BindingDB Entry DOI: 10.7270/Q23B62DG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM359614 (N-[(1-Aminoisoquinolin-6-yl)methyl]-({4-[(4-methyl...) Show SMILES Cc1cnn(Cc2ccc(Cc3cncc(c3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 Show InChI InChI=1S/C28H26N6O/c1-19-13-33-34(17-19)18-21-4-2-20(3-5-21)10-23-12-25(16-30-14-23)28(35)32-15-22-6-7-26-24(11-22)8-9-31-27(26)29/h2-9,11-14,16-17H,10,15,18H2,1H3,(H2,29,31)(H,32,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.86	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US10221161 (2019) BindingDB Entry DOI: 10.7270/Q23B62DG
					More data for this Ligand-Target Pair